Scaling Down of Biopharmaceutical Unit Operations — Part 2: Chromatography and Filtration - Constraints associated with equipment can make scale-down a challenging exercise. - BioPharm


Scaling Down of Biopharmaceutical Unit Operations — Part 2: Chromatography and Filtration
Constraints associated with equipment can make scale-down a challenging exercise.

BioPharm International

Anurag Rathore
Creation and qualification of scale-down models is essential for performing several critical activities that support process validation and commercial manufacturing. This combined article is the fifth in the "Elements of Biopharmaceutical Production" series. Part 1 (March 2005) covered fermentation. In this segment, we present some guidelines and examples for scale-down of common downstream unit operations used in biotech processes — chromatography and filtration.

CHROMATOGRAPHY SCALE-DOWN In theory, chromatography is one of the more straightforward unit operations to scale down. Factors at the large scale such as column-header design and packing can be difficult to control and may result in reduced accuracy of the scale-down model. This section presents a review of general guidelines for scaling down.

Use representative feed streams, preferably from full-scale manufacturing. First perform a complete analysis of product concentration, quality attributes, and other feed stream characteristics (such as pH and conductivity) to ensure a good match. If possible, use feed streams from different lots at small scale to learn about the effect of feed stream quality on the performance. In addition, acquire some knowledge of the storage and stability of the feed stream material. Storage-related degradation of the inventory could affect the outcome of the small-scale runs.

Use a representative chromatography resin. It would be ideal to have resin from the lot being used at full scale. If you can't obtain GMP-released resin, then make a match based on the vendor's certificate of analysis.

Buffers and other solutions should be made up and released by manufacturing. If it is not possible to obtain these, mix solutions with GMP-released raw materials, or material of an equivalent grade from an approved vendor. Follow exactly the solution recipes from manufacturing. The pH, temperature, and conductivity probes that check buffer properties must be comparable with those used at the large scale. Measure pH and conductivity at the same temperature spelled out in the recipe. The pH and conductivity standards should also be comparable (preferably identical) to those used in manufacturing.

Hardware Our experience has been that an automated small-scale chromatography system, such as the äKTA Explorer, excels at small-scale studies. It offers precise, accurate, and reproducible control of flow rates and gradients. However, you still have to check and calibrate the accuracy and precision of in-line detectors (pH, conductivity, temperature) by using off-line probes.

Table 1. Comparison of Scale-down Model to Large-scale Cation-exchange Column.3 Input material roughly 98 percent antibody, 3 ppm DNA, 3,000 ppm CHOP and <7.8 ppm Protein A. (Reference 3 shows intermediate cycles.)
The type of column is generally not a major issue; however, whenever possible use the same bed support material. We prefer to not use column diameters of less than 1.0 cm since the ratio of system dead volume to column volume can result in pool concentrations significantly lower than those seen at large scale. The packing procedures and solutions should be similar to those used at large scale.

blog comments powered by Disqus



New Tax Rules May Deter Future Pharma M&A
October 1, 2014
NIH Seeks to Improve Vaccine Response with New Adjuvants
September 30, 2014
New Report Details Players and Pipelines in the Biosimilar Space
September 30, 2014
Baxter International Plans to Open R&D Center for Baxalta
September 30, 2014
FDA Releases First-Ever Purple Book for Biosimilar Characterization
September 26, 2014
Author Guidelines
Source: BioPharm International,
Click here